Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Bristol Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY EXEL
Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
From Bristol Myers Squibb
Via Business Wire
Tickers BMY RYZB
Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
From Bristol Myers Squibb
Via Business Wire
Tickers BMY TSVT
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Dividend Increase
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY TSVT
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb’s First Disclosures and New Data at ASH 2023 Highlight Company’s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.